Skip Navigation


Annals of Oncology Advance Access originally published online on February 14, 2007
Annals of Oncology 2007 18(5):851-858; doi:10.1093/annonc/mdl502
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow An erratum has been published
Right arrow All Versions of this Article:
18/5/851    most recent
mdl502v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (18)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Apostolaki, S
Right arrow Articles by Mavroudis, D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Apostolaki, S
Right arrow Articles by Mavroudis, D
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

breast cancer

Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance

S Apostolaki1, M Perraki1, A Pallis2, V Bozionelou2, S Agelaki2, P Kanellou2, A Kotsakis2, E Politaki1, K Kalbakis2, A Kalykaki2, L Vamvakas2, V Georgoulias1,2 and D Mavroudis1,2,*

1 Laboratory of Tumor Cell Biology, School of Medicine, University of Crete
2 Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece

* Correspondence to: Dr D. Mavroudis, Department of Medical Oncology, University General Hospital of Heraklion, PO Box 1352, Heraklion 711 10, Crete, Greece. Tel: +30-2810-392823; Fax: +30-2810-392802; E-mail: mavrudis{at}med.uoc.gr

Background: The purpose of this study was to evaluate the prognostic value of circulating tumor cells (CTCs) expressing HER2 messenger RNA (mRNA) after the administration of adjuvant chemotherapy in women with operable breast cancer.

Patients and methods: HER2 mRNA-positive CTCs were detected by nested RT-PCR in the peripheral blood of 214 patients with stage I and II breast cancer after the completion of adjuvant chemotherapy.

Results: HER2 mRNA-positive CTCs were detected in 45 (21%) patients. Adjuvant chemotherapy could eliminate HER2 mRNA-positive CTCs in 16 (30.2%) prechemotherapy-positive patients. Moreover, HER2 mRNA-positive CTCs were detected in eight (5%) of 161 prechemotherapy-negative patients. The detection of HER2 mRNA-positive CTCs after chemotherapy was associated with reduced disease-free interval (DFI) (P = 0.006) but not with overall survival (P = 0.2); this effect was mainly observed in node-negative patients (P = 0.04) and to a lesser extent in node-positive (P = 0.06). Multivariate analysis revealed that the detection of HER2 mRNA-positive CTCs was an independent predictive factor for DFI (hazard ratio 3.238, P < 0.0005).

Conclusions: The detection of HER2 mRNA-positive CTCs after the completion of adjuvant chemotherapy may provide clinically useful information concerning the efficacy of treatment and the prognosis of patients with operable breast cancer.

Key words: adjuvant chemotherapy, CTCs, early breast cancer, HER2 mRNA, occult tumor cells

Received for publication October 5, 2006. Revision received December 5, 2006. Accepted for publication December 18, 2006.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Anticancer ResHome page
N. KRAWCZYK, M. BANYS, H. NEUBAUER, E.-F. SOLOMAYER, C. GALL, M. HAHN, S. BECKER, R. BACHMANN, D. WALLWIENER, and T. FEHM
HER2 Status on Persistent Disseminated Tumor Cells after Adjuvant Therapy May Differ from Initial HER2 Status on Primary Tumor
Anticancer Res, October 1, 2009; 29(10): 4019 - 4024.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Alix-Panabieres, S. Riethdorf, and K. Pantel
Circulating Tumor Cells and Bone Marrow Micrometastasis
Clin. Cancer Res., August 15, 2008; 14(16): 5013 - 5021.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Ignatiadis, G. Kallergi, M. Ntoulia, M. Perraki, S. Apostolaki, M. Kafousi, G. Chlouverakis, E. Stathopoulos, E. Lianidou, V. Georgoulias, et al.
Prognostic Value of the Molecular Detection of Circulating Tumor Cells Using a Multimarker Reverse Transcription-PCR Assay for Cytokeratin 19, Mammaglobin A, and HER2 in Early Breast Cancer
Clin. Cancer Res., May 1, 2008; 14(9): 2593 - 2600.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
K. Pantel, C. Alix-Panabieres, and S. Riethdorf
Circulating Tumor Cells: Detection and Clinical Relevance
Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 603 - 610.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.